2010
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2010, 72: 744-50. PMID: 21034692, DOI: 10.4088/jcp.09m05659gre.Peer-Reviewed Original ResearchConceptsDepression Rating ScaleRating ScaleMean changeWeek 6Clinical Global Impression-Bipolar Version ScaleBipolar disorderHamilton Depression Rating Scale scoresMontgomery-Åsberg Depression Rating ScalePlacebo-controlled clinical trialDepression Rating Scale scoresHamilton Depression Rating ScaleYoung Mania Rating ScaleAdjunctive levetiracetam therapyLevetiracetam adjunctive therapySecondary efficacy assessmentsBipolar disorder type IPlacebo-controlled trialHamilton Anxiety Rating ScalePrimary efficacy measureSecondary outcome measuresMajor depressive episodeRating Scale scoresMania Rating ScaleShort-term treatmentSignificant differences
2003
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects
2001
Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low
Rabiner E, Bhagwagar Z, Gunn R, Sargent P, Bench C, Cowen P, Grasby P. Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal Of Psychiatry 2001, 158: 2080-2082. PMID: 11729033, DOI: 10.1176/appi.ajp.158.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainDepressive Disorder, MajorDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPindololReceptors, SerotoninReceptors, Serotonin, 5-HT1Selective Serotonin Reuptake InhibitorsTomography, Emission-ComputedTreatment OutcomeConceptsPositron emission tomographyDose of pindololClinical trialsDepressed patientsSelective serotonin reuptake inhibitorsSignificant occupancyPresent clinical trialSerotonin reuptake inhibitorsPindolol augmentationAntidepressant medicationReuptake inhibitorsPET evidenceEmission tomographyPindololTrialsDoseAutoreceptorsMedicationsPatientsInconsistent resultsEfficacyVast majorityDoses